Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

statements that can be identified by terminology such as "potential," "to present," "to show," "to demonstrate," "can," "will," "to explore," "pipeline," or similar expressions, or by express or implied discussions regarding potential new indications or labeling, or potential marketing approvals for the products described in this release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any of the products or additional indications or labeling described in this release will be submitted for approval or approved for sale in any market. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove inco
'/>"/>
SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... YORK , May 5, 2015  IBM Watson ... is collaborating with more than a dozen leading cancer ... and personalize treatment options for their patients. The institutes ... capabilities to reduce from weeks to minutes the ability ... and gather relevant information from medical literature to personalize ...
(Date:5/5/2015)... EXTON, Pa. , May 5, 2015  The ... global leader in pharmacokinetic testing of drugs and safety ... Gum , Associate Director of Preclinical Studies, presented at ... in Vision and Ophthalmology (ARVO) in Denver, ... presentation was "Safety Assessment of a Novel, Cross-Linked, Bio-Absorbable ...
(Date:5/5/2015)... 2015  American Laboratory Trading, Inc. (ALT), the leading ... industry veteran Anggie Becorest as their new ... based out of the company,s San Diego ... the company,s west coast operations, diversifying the company,s offerings, ... has been the leader in the refurbished lab equipment ...
Breaking Medicine Technology:Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3ALT Names Anggie Becorest Senior Vice President of Business Development 2
(Date:5/5/2015)... New York, New York (PRWEB) May 05, ... treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) filed on ... cardiovascular complications due to their use of ... forward in the federal multidistrict litigation underway ... Illinois. According to court documents dated May ...
(Date:5/5/2015)... Viverae®, a health management and engagement ... multinational developer, manufacturer and marketer of innovative, life-enhancing ... oncology and surgical specialty products, as the recipient ... Award recognizes outstanding achievement in the design and ... client base. , Viverae reviewed the employee wellness ...
(Date:5/5/2015)... Jacksonville, Fla. (PRWEB) May 05, 2015 ... from the Commission on Cancer (CoC) of the American ... a cancer program must meet more than 30 Commission ... years through a survey process, and maintain levels of ... , When patients choose to seek care locally ...
(Date:5/5/2015)... Patricia George knows all too well the debilitating effects ... specialist at the University of Pittsburgh Medical Center (UPMC), ... idea entered her mind for Team PHenomenal Hope. ... 2010 PHA International Conference,” George recalled. “The speakers – ... climb up Mt. Kilimanjaro and I remember thinking how ...
(Date:5/5/2015)... Atlanta, Georgia (PRWEB) May 05, 2015 ... Software of Victoria BC announced the Skedans Sensor ... The platform, for mobile and web app developers, provides ... from airborne and mobile sensors. , The Skedans Sensor ... at the intersection of the Internet of Things, Web ...
Breaking Medicine News(10 mins):Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2
... abstain from promiscuous sex on 1 December 2005, the World ... // and ignorance with regard to AIDS are contributing towards ... Stephen Lewis, has called upon the world’s rich nations to ... is continuing to take a heavy toll in the African ...
... DNA vaccine trials conducted against the AIDS/HIV virus. The ... completed among 40 HIV- negative // volunteers. ... of vaccine biology. It involves direct injection of one ... human body. These vaccines precipitate an immune response so ...
... Medical Center shows that patient trust over their doctors would ... // death were to be enforced in the near future. ... a telephonic survey conducted among a group of 1,117 adults ... attitudes about physician aid in dying. The participants were required ...
... University of Michigan researchers says that women are better at ... this conclusion after tracking 490 heart patients, who were treated ... pain. ,All these patients had enrolled in the ... about themselves plus gave the limit that their heart could ...
... the increase in the fees for lab tests and treatment ... that this was necessary to maintain the quality of the ... is taking place at the institution since 1995. The budget ... revenue generated by it is only between Rs.12 to Rs.25 ...
... Breast cancer is more likely to occur in the case ... do not smoke at all, or start smoking later in ... at Rochester have revealed this. Women who start smoking before ... breast cancer. ,In comparison, women who started smoking after ...
Cached Medicine News:Health News:DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope 2
... CycloPhotocoagulation (ECP) is a surgical approach to ... visualized laser application. The ciliary body (which ... surgeon, from the anterior or posterior segment, ... target tissues are easily and accurately identified ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqueous ... the anterior or posterior segment, through the ... are easily and accurately identified utilizing endoscopy. ...
Medicine Products: